Obe­si­ty deals come in­to fo­cus af­ter Roche shells out $2.7B for Car­mot

Roche’s $2.7 bil­lion bolt-on deal for Car­mot Ther­a­peu­tics is the lat­est ex­am­ple of how phar­ma com­pa­nies are rac­ing to get back in­to obe­si­ty, drug de­vel­op­ment’s most prized field, an­a­lysts told End­points News.

The Mon­day morn­ing deal came on the heels of Pfiz­er’s dis­clo­sure last Fri­day that it wouldn’t move its obe­si­ty as­set, danuglipron, in­to Phase III test­ing.

“The news about Pfiz­er just re­it­er­at­ed the im­por­tance of a once-dai­ly oral and mak­ing sure that you can achieve the ef­fi­ca­cy that you want with­out nec­es­sar­i­ly sac­ri­fic­ing the [ad­verse event] pro­file,” Car­mot CEO Heather Turn­er told End­points News. “Ul­ti­mate­ly, that’s what was the chal­lenge with danuglipron.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER